[go: up one dir, main page]

NO20083955L - Nye kromen-2-on-derivater og deres anvendelse som monoaminneurotransmittergjenopptaksinhibitorer - Google Patents

Nye kromen-2-on-derivater og deres anvendelse som monoaminneurotransmittergjenopptaksinhibitorer

Info

Publication number
NO20083955L
NO20083955L NO20083955A NO20083955A NO20083955L NO 20083955 L NO20083955 L NO 20083955L NO 20083955 A NO20083955 A NO 20083955A NO 20083955 A NO20083955 A NO 20083955A NO 20083955 L NO20083955 L NO 20083955L
Authority
NO
Norway
Prior art keywords
alkyl
group
reuptake inhibitors
derivatives
monoamine neurotransmitter
Prior art date
Application number
NO20083955A
Other languages
English (en)
Inventor
Dan Peters
Elsebet Ostergaard Nielsen
John Paul Redrobe
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of NO20083955L publication Critical patent/NO20083955L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)

Abstract

Som kan anvendes som monoaminnevrotransmitter gjenopptaksinhibitorer. I andre aspekter vedrører oppfinnelsen anvendelse av disse forbindelsene i en fremgangsmåte for terapi, og farmasøytiske preparater som omfatter forbindelsene ifølge oppfinnelsen. Formel (I) hvor Q er en kromen-2-on-gruppe; hvor kromen-2-on-gruppen eventuelt er substituert med én eller flere substituenter uavhengig av hverandre valgt fra gruppen bestående av: halo, trifluormetyl, trifluormetoksy, cyano, hydroksy, amino, nitro, alkoksy, syklo-alkoksy, alkyl, sykloalkyl, sykloalkylalkyl, alkenyl og alkynyl; R1 er hydrogen eller alkyl; hvor alkyl er eventuelt substituert med én eller flere substituenter uavhengig av hverandre valgt fra gruppen bestående av: halo, trifluormetyl, trifluormetoksy, cyano, hydroksy, amino, nitro, alkoksy, syklo-alkoksy, alkyl, sykloalkyl, sykloalkylalkyl, alkenyl og alkynyl; og R2 og R3 danner til sammen -(CH2)-(CH2)- eller -(CH)=(CH>.
NO20083955A 2006-02-17 2008-09-16 Nye kromen-2-on-derivater og deres anvendelse som monoaminneurotransmittergjenopptaksinhibitorer NO20083955L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600233 2006-02-17
US77466906P 2006-02-21 2006-02-21
PCT/EP2007/051401 WO2007093604A1 (en) 2006-02-17 2007-02-13 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Publications (1)

Publication Number Publication Date
NO20083955L true NO20083955L (no) 2008-09-16

Family

ID=39272807

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083955A NO20083955L (no) 2006-02-17 2008-09-16 Nye kromen-2-on-derivater og deres anvendelse som monoaminneurotransmittergjenopptaksinhibitorer

Country Status (15)

Country Link
US (1) US8153797B2 (no)
EP (2) EP1989202B1 (no)
JP (1) JP2009526816A (no)
KR (1) KR20080096833A (no)
CN (1) CN101405287B (no)
AR (1) AR059546A1 (no)
AU (1) AU2007216535A1 (no)
BR (1) BRPI0707853A2 (no)
CA (1) CA2641916A1 (no)
IL (1) IL192485A0 (no)
NO (1) NO20083955L (no)
RU (1) RU2008129865A (no)
TW (1) TW200800980A (no)
WO (1) WO2007093604A1 (no)
ZA (1) ZA200805908B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070061846A (ko) * 2004-09-30 2007-06-14 뉴로서치 에이/에스 신규한 크로멘-2-온 유도체 및 모노아민 신경전달물질재흡수 억제제로서의 이의 용도
CA2673315A1 (en) * 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP2010513392A (ja) * 2006-12-20 2010-04-30 ノイロサーチ アクティーゼルスカブ 新規クロメン−２−オン誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのそれらの使用
AU2010247514A1 (en) 2009-05-15 2011-11-17 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20130040985A1 (en) 2010-01-29 2013-02-14 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2011117289A1 (en) 2010-03-25 2011-09-29 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neuro-transmitter re-uptake inhibitors
WO2012000881A1 (en) 2010-07-02 2012-01-05 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923209D0 (en) * 1989-10-14 1989-11-29 Wyeth John & Brother Ltd Heterocyclic compounds
EE03566B1 (et) 1995-11-02 2001-12-17 Neurosearch A/S Kondenseerunud tropaanderivaadid, nende valmistamine ja kasutamine
DE69705608T2 (de) 1996-02-22 2002-05-16 Neurosearch A/S, Ballerup Tropanderivate, deren herstellung und verwendung
US5916914A (en) * 1997-08-08 1999-06-29 Warner-Lambert Company Compounds and method of treating psychosis and schizophrenia
JP2005508872A (ja) 2001-05-23 2005-04-07 ニューロサーチ、アクティーゼルスカブ トロパン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害剤として使用する方法
AU2003243497A1 (en) 2002-06-12 2003-12-31 Millennium Pharmaceuticals, Inc. Antagonists of melanin concentrating hormone receptor
US7538233B2 (en) 2003-09-05 2009-05-26 Aventis Pharmaceuticals Inc. Coumarins as iNOS inhibitors
BRPI0515261A (pt) * 2004-09-30 2008-07-15 Neurosearch As composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo
US7781456B2 (en) 2004-12-17 2010-08-24 Neurosearch A/S Enantiomers of 3-heteroaryl-8H-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors
CA2673315A1 (en) 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP2010513392A (ja) 2006-12-20 2010-04-30 ノイロサーチ アクティーゼルスカブ 新規クロメン−２−オン誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのそれらの使用

Also Published As

Publication number Publication date
AR059546A1 (es) 2008-04-09
AU2007216535A1 (en) 2007-08-23
EP1989202A1 (en) 2008-11-12
EP1989202B1 (en) 2012-07-25
CN101405287A (zh) 2009-04-08
US20100227883A1 (en) 2010-09-09
BRPI0707853A2 (pt) 2011-05-10
CA2641916A1 (en) 2007-08-23
WO2007093604A1 (en) 2007-08-23
KR20080096833A (ko) 2008-11-03
IL192485A0 (en) 2009-02-11
US8153797B2 (en) 2012-04-10
JP2009526816A (ja) 2009-07-23
TW200800980A (en) 2008-01-01
ZA200805908B (en) 2009-10-28
EP2311835A1 (en) 2011-04-20
RU2008129865A (ru) 2010-03-27
CN101405287B (zh) 2011-05-18

Similar Documents

Publication Publication Date Title
NO20083955L (no) Nye kromen-2-on-derivater og deres anvendelse som monoaminneurotransmittergjenopptaksinhibitorer
EA201270646A1 (ru) Ингибиторы глюкозилцерамидсинтазы
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
CU24030B1 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
EA201100189A1 (ru) Гетероарильные производные в качестве ингибиторов dgat1
EA200970156A1 (ru) Пиридизиноновые производные
DK2035379T3 (da) Inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
MX2011009146A (es) Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh.
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
DK2021337T3 (da) Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1
NO20083480L (no) Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister
WO2010091104A8 (en) Glucosylceramide synthase inhibitors
GEP20125712B (en) Method for preparation of piperazine compounds and hydrochloride salts thereof
NO20084186L (no) Nye aminer
NO20083738L (no) Sekundaere aminer som renininhibitorer
ECSP099351A (es) Compuestos heterociclicos y su uso como inhibidores de la
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
MX2008016558A (es) Preparacion y aplicacion terapéutica de derivados de 2-benzoil-imidazopiridinas.
NO20060360L (no) Nye 8-azabisyklo [3.2.1] oktanderivater og deres anvendelse som monoaminneurotransmittergjenopptaksinhibitorer
MX2009005916A (es) Nuevos derivados de cromen-2-ona y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina.
NO20092719L (no) Nye kromen-2-on-derivater og deres anvendelse som monoaminneurotransmitter-gjenopptaksinhibitorer
TW200604173A (en) Novel compounds
NO20070329L (no) Nye alkylsubstituerte piperazinderivater og deres anvendelse som monoaminneurotransmittergjenopptaksinhibitorer
AR064457A1 (es) Derivados de 7-[(8-aza-biciclo[3,2,1]oct-3-il)-oxi]-3-heteroaril-2-il-cromen-2-ona una composicion farmaceutica que los comprende y su uso para la elaboracion de un medicamento para el tratamiento de una enfermedad mediada por la ssri
NO20081289L (no) Derivater av 5-pyridazinyl-1-azabicyklo[3.2.1]oktan, deres fremstilling og deres anvendelse i terapien

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application